-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 8, 2021, Autolus Therapeutics announced that it has reached a strategic cooperation and financing agreement with Blackstone Life Sciences
Obe-cel aims to overcome the limitations of current CAR-T cell therapy in terms of clinical activity and safety
In the trial data released in June this year, obe-cel achieved a 100% complete remission rate in a cohort of patients for the treatment of indolent B-cell non-Hodgkin's lymphoma (iNHL)
▲Obe-cel's performance in the treatment of ALL patients (picture source: Autolus official website)
Reference materials:
[1] Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform.